Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Update on Active Biotech's TTS products under clinical development

Jan. 17, 2001

Telik and the University of Arizona enter TRAP alliance

Jan. 17, 2001

Genome-derived candidate for oncology identified as part of Millennium/Bayer alliance

Jan. 17, 2001

Xcytrin clinical development program update

Jan. 16, 2001

New antitumor prodrugs activated by FAPalpha

Jan. 15, 2001

Inhibitors of growth factor receptor tyrosine kinases developed at BMS

Jan. 15, 2001

Sonus begins phase I evaluation of less toxic form of paclitaxel

Jan. 15, 2001

Sanofi-Synthelabo to market Leuprogel in the U.S. and Canada

Jan. 12, 2001

NCI and Biovest may enter B-cell lymphoma vaccine collaboration

Jan. 12, 2001

Preparation and use of cyclin-dependent kinase inhibitors

Jan. 11, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...